pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Drugs
by stage
  • Marketed
  • Phase 3
  • Phase 2
  • Phase 1
  • Preclinical
browse
  • Most catalysts
  • Recently active
  • All drugs →
  • Companies
  • Patent cliff
Calendar
what
  • Trial readouts
  • PDUFA dates
  • Approvals
  • Earnings
when
  • Upcoming
  • Month grid
  • Recently passed
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
  • Drugs
  • Calendar
  • Companies
Hubs
  • Topics
  • Patent cliff
  • Publications
  • Readouts
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
STAT·Jul 23·1 min read
save

Congress rushes health-care bills on price transparency and prior authorization before August recess

Jul 23, 2026·read at STAT ↗RegulatoryNeutral

Congress is trying to pass a bundle of health-care legislation in the final week before the House and Senate adjourn for the August recess.

Lawmakers are focusing on measures that would increase price transparency for medical services and drugs, aiming to give patients clearer cost information.

Another priority is reforming prior-authorization procedures, with proposals intended to streamline the process and reduce delays in patient care.

The flurry of activity comes as both chambers will be in session separately for part of the period, adding pressure to move bills quickly before the September recess.

source

This writeup was produced by pharmadog from original reporting by STAT.

Original headline: “STAT+: What’s in the last-minute flurry of health care bills?”

read at STAT ↗
431 words · retrieved Jul 23
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

companies
Ultragenyx Pharmaceutical Inc.
drugs
Rare Disease
topics
GLP-1 receptorRare Disease

related stories

  • Sep 14Novo drops ‘Nordisk’ moniker, turns bull toward future in corporate rebrandBioSpace
  • Sep 8Structure’s obesity portfolio impresses on GLP-1 and amylin fronts in dual data dropBioSpace
  • Sep 4This week in charts: China deals, stock flatlines and Lilly’s M&A spreeBioPharma Dive
  • Aug 31STAT+: We’re reading about drug pricing deals, a new cancer therapy approval, and moreSTAT
  • Aug 28Lilly joins Novo in cardiovascular space after FDA nod for GLP-1/GIP agonist MounjaroBioSpace